Huadong Pharmaceutical Company
Huadong Pharmaceutical Company, also known as Huadong Medicine Co., Ltd., is a prominent player in the pharmaceutical industry, headquartered in Hangzhou, China. Established in 1993, the company has expanded its operations across various regions, including East Asia and beyond, solidifying its presence in the global market. Specialising in the research, development, and manufacturing of innovative pharmaceuticals, Huadong focuses on areas such as oncology, cardiovascular health, and anti-infectives. Its commitment to quality and cutting-edge technology has led to the development of unique products that cater to diverse medical needs. With a strong market position, Huadong Pharmaceutical has achieved significant milestones, including numerous certifications and partnerships that enhance its reputation. The company continues to strive for excellence, contributing to advancements in healthcare and improving patient outcomes worldwide.
DitchCarbon Score
How does Huadong Pharmaceutical Company's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Chemicals industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Huadong Pharmaceutical Company's score of 7 is lower than 92% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Huadong Pharmaceutical Company's reported carbon emissions
In 2023, Huadong Pharmaceutical Company reported carbon emissions of approximately 14.3 million tonnes CO2e, with Scope 1 emissions accounting for about 14.3 million tonnes CO2e and total Scope 1 and 2 emissions reaching around 152.1 million tonnes CO2e. This marks an increase from 2022, where the company recorded about 11.3 million tonnes CO2e in Scope 1 emissions and total Scope 1 and 2 emissions of approximately 108.6 million tonnes CO2e. Despite the rise in emissions, there are currently no publicly available reduction targets or significant climate commitments outlined by Huadong Pharmaceutical. The company has not specified any initiatives under the Science Based Targets initiative (SBTi) or other recognised climate pledges. As the pharmaceutical industry increasingly focuses on sustainability, Huadong's emissions data highlights the need for enhanced climate strategies and commitments to align with global climate goals.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project2022 | 2023 | |
|---|---|---|
| Scope 1 | 11,305,600 | 00,000,000 |
| Scope 2 | - | - |
| Scope 3 | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Huadong Pharmaceutical Company is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
